PRE Stock Forecast & Price Target

Prenetics Global is attractive because IM8 is scaling rapidly in a massive $400 billion to $500 billion dietary supplements market, with FY26 revenue guidance lifted to $210 million to $220 million and an annualized run-rate expected to reach $300 million. Its fundamentals are strengthened by 3:1 LTV/CAC, roughly $140 million of cash and equivalents, and subscription economics that raise average order value to $240, accelerate cash collection 3x, and support high renewals. The outlook is further reinforced by strong clinical validation, gross margin expansion to 64% in 1Q26, diversified marketing channels, and a clear product expansion pipeline targeting adjacent categories and repeat customer revenue.

Prenetics Global is viewed negatively because its growth model remains heavily dependent on sales and marketing spending that is expected to stay north of 60% of revenue in FY2026, even as management works to scale IM8 to $204M of revenue. Despite a gross margin of 64.6% and an implied LTV/CAC of ~3:1, the company still expects an adjusted EBITDA loss of ($26.5M) for the year, highlighting limited near-term operating leverage. Its transition toward longer-duration quarterly subscribers has raised acquisition costs, while exposure to digital ad rate changes, platform algorithm shifts, privacy regulations, and global fulfillment expenses adds further risk to reaching sustainable profitability.